Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 528,200 shares, a decline of 18.1% from the October 15th total of 644,700 shares. Currently, 2.1% of the company’s stock are short sold. Based on an average daily trading volume, of 159,300 shares, the days-to-cover ratio is presently 3.3 days.

Analysts Set New Price Targets

Separately, William Blair upgraded shares of Vistagen Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th.

Vistagen Therapeutics Trading Down 3.7 %

Shares of NASDAQ:VTGN opened at $2.63 on Friday. The stock has a market capitalization of $73.22 million, a PE ratio of -2.12 and a beta of 0.78. Vistagen Therapeutics has a 1 year low of $2.58 and a 1 year high of $5.86. The firm has a fifty day moving average price of $3.04 and a 200 day moving average price of $3.49.

Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.30 million. During the same quarter in the prior year, the firm posted ($0.94) EPS. On average, sell-side analysts forecast that Vistagen Therapeutics will post -1.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vistagen Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VTGN. American Century Companies Inc. boosted its holdings in shares of Vistagen Therapeutics by 49.1% during the 2nd quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock worth $105,000 after buying an additional 9,984 shares during the period. Jane Street Group LLC acquired a new position in Vistagen Therapeutics during the 3rd quarter worth $59,000. Blair William & Co. IL boosted its holdings in Vistagen Therapeutics by 29.2% during the second quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock valued at $308,000 after acquiring an additional 20,000 shares during the period. HighTower Advisors LLC acquired a new stake in shares of Vistagen Therapeutics in the third quarter valued at about $64,000. Finally, Acadian Asset Management LLC bought a new position in shares of Vistagen Therapeutics in the first quarter worth about $169,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.